Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543862 | 0.99 | LRRK2 (0.58) | LRRK2IKBKBCHUKARCDC7 | |
| SCHEMBL3579471 | 0.78 | CHUK (0.47) | LRRK2IKBKBCHUKARCYP19A1 | |
| SCHEMBL3579472 | 0.77 | LRRK2 (0.42) | LRRK2IKBKBCHUKARCYP19A1 | |
| SCHEMBL3567725 | 0.72 | LRRK2 (1.00) | LRRK2IKBKBCHUKCDC7 | |
| SCHEMBL3573465 | 0.72 | LRRK2 (0.38) | LRRK2BRAF | |
| SCHEMBL16186389 | 0.70 | LRRK2 (0.46) | LRRK2CHUK | |
| SCHEMBL3575954 | 0.68 | LRRK2 (0.67) | LRRK2IKBKBCHUK | |
| SCHEMBL3578783 | 0.68 | HSP90AB1 (0.51) | — | |
| SCHEMBL1028218 | 0.66 | ESR2 (0.65) | LRRK2ARCYP19A1 | |
| SCHEMBL16177865 | 0.65 | LRRK2 (0.42) | LRRK2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | LRRK2 2502/4885IKBKB 1396/4885CHUK 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.